Last Updated: May 2026
Gonadorelin is a synthetic 10-amino-acid peptide identical to native gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. It directly stimulates the pituitary GnRH receptor to drive LH and FSH release, with downstream effects on gonadal steroid production. Gonadorelin is FDA-approved as Factrel for diagnostic evaluation of pituitary gonadotropic function and has historic approval for certain fertility and hypogonadism indications, though the Factrel product was discontinued from the US market in 2020 for commercial reasons. Gonadorelin is widely used in research contexts and incorporated into hormone replacement and testosterone-restart protocols.
Gonadorelin is a synthetic 10-amino-acid peptide identical in sequence to native gonadotropin-releasing hormone (GnRH, also LHRH), produced by the hypothalamus and acting on the pituitary GnRH receptor to stimulate LH and FSH release in pulsatile fashion. This downstream gonadotropin signal drives testicular testosterone production (in males) and ovarian follicular development and ovulation (in females). The short native half-life (3–10 minutes) and need for pulsatile administration to avoid pituitary desensitization are the key pharmacokinetic constraints. Evidence level: Established endocrinology; FDA-approved as Factrel (diagnostic); extensive clinical research base across reproductive endocrinology.
Gonadorelin's clinical evidence base spans diagnostic evaluation of pituitary gonadotropic function (the Factrel approved indication), pulsatile administration via infusion pump for hypothalamic hypogonadism and ovulation induction, and adjunctive use in testosterone replacement therapy (TRT) protocols to maintain endogenous testicular function. The TRT adjunctive use has expanded in functional medicine and men's health practice, often replacing or complementing hCG (human chorionic gonadotropin) for testicular function preservation during exogenous testosterone therapy. Evidence level: FDA-approved diagnostic; extensive clinical research; established endocrinology practice including TRT adjunctive use.
Gonadorelin acts at the pituitary GnRH receptor — downstream of Kisspeptin (which stimulates the hypothalamic GnRH neurons that produce native gonadorelin/GnRH).
| Compound | Mechanism level | Primary use | FDA status |
|---|---|---|---|
| Kisspeptin | Hypothalamic GnRH neuron stimulation | Fertility research | Phase 1/2 |
| Gonadorelin | Pituitary GnRH receptor | Diagnostic, TRT support, fertility | FDA-approved (Factrel, discontinued) |
| GnRH analogs (leuprolide) | Pituitary GnRH receptor (sustained) | Endocrine suppression | FDA-approved |
| hCG | Gonadal LH receptor | TRT support, fertility | FDA-approved |
Gonadorelin has an extensive clinical safety record with mild side effects — injection-site reactions, occasional transient flushing, and rare hypersensitivity reactions. The short half-life and physiological mechanism mean side effects are generally less pronounced than with sustained GnRH analogs (which produce paradoxical pituitary desensitization through receptor downregulation). Long-term safety at sustained intermittent dosing in TRT-adjunctive use is reasonably well-characterized in clinical practice contexts. Evidence level: Extensive clinical safety; TRT-adjunctive long-term use in clinical practice; rare hypersensitivity well-documented.
Gonadorelin was FDA-approved as Factrel (1989, discontinued from US market 2020 for commercial reasons) for diagnostic evaluation of pituitary gonadotropic function. It is currently available in the US through compounding pharmacies under 503A and 503B regulations, with the compounding pharmacy pathway depending on FDA regulatory status that has been in flux during 2024–2026. Internationally, gonadorelin has approved status in several jurisdictions for fertility and hypogonadism indications. Current status in FDA peptide regulation 2025–2026 timeline.
Gonadorelin is widely sold across pharmacy-compounded and research-grade supply chains with substantial quality variance — and the structural similarity to GnRH analogs (leuprolide, triptorelin) requires mass spectrometry verification. Independent HPLC purity testing is the standard quality signal. Pharmacy-grade compounded gonadorelin (for TRT-adjunctive use) carries different quality assurance than research-grade material. Guidance in how-to-test-peptides hub.
Peptigrity purchases Gonadorelin vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
Gonadorelin stimulates the pituitary GnRH receptor to drive LH and FSH release in pulsatile fashion, with downstream effects on gonadal steroid production. Clinical uses include diagnostic evaluation, fertility/ovulation induction, and adjunctive testosterone replacement therapy for testicular function preservation.
Gonadorelin was FDA-approved as Factrel for diagnostic use but was withdrawn from the US market in 2020 for commercial reasons. It remains available through compounding pharmacies in the US and has approved status in several international jurisdictions. The Factrel withdrawal was not safety-related.
Compounded gonadorelin is available through US compounding pharmacies (503A/503B) under physician prescription. Research-grade gonadorelin is legal to purchase as a research chemical for laboratory use in most jurisdictions. Country breakdown in peptide legal status guide.
Exogenous testosterone administration suppresses endogenous LH production through negative feedback, which can lead to testicular atrophy and reduced sperm production. Gonadorelin (mimicking natural GnRH pulses) stimulates pituitary LH release and maintains testicular function. This use is well-established in functional medicine and men's health practice though not specifically FDA-approved for this indication.
Gonadorelin acts at the pituitary GnRH receptor (one step upstream); hCG acts directly at the testicular LH receptor (one step downstream). Both maintain testicular function during exogenous testosterone therapy but through different mechanisms. Gonadorelin produces a more physiological pattern; hCG produces direct LH-receptor stimulation.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation distinguishing gonadorelin from GnRH analogs. COA interpretation in red flags in peptide certificates of analysis.
No. Gonadorelin clinical use protocols vary by indication — pulsatile pump infusion for fertility, intermittent subcutaneous dosing for TRT-adjunctive use, single-dose IV for diagnostic evaluation. Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Gonadorelin was FDA-approved as Factrel (discontinued from US market 2020) and is currently available through US compounding pharmacies. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.